Table 5.
Multivariate analysis of DRFS in the Neoadjuvant cohort (non-black patients separated)
| Characteristic | p-value | Hazard ratio |
|---|---|---|
| Black1 | 0.08 | 2.09 (0.91–4.79) |
| Hispanic | 0.33 | 1.57 (0.63–3.94) |
| Other | 0.95 | 0.99 (0.29–3.16) |
| Clinical stage III | <0.0001 | 3.09 (1.77–5.40) |
| Age <50 | 0.78 | 1.08 (0.65–1.79) |
| ER− | 0.32 | 1.51 (0.67–3.41) |
| Triple-negative | 0.27 | 1.60 (0.70–3.68) |
| Multivariate analysis of DRFS
in the Neoadjuvant cohort (non-black patients pooled together) | ||
|---|---|---|
| Characteristic | p-value | Hazard ratio |
| Black2 | 0.05 | 1.68 (1.00–2.85) |
| Clinical stage III | <0.0001 | 3.18 (1.83–5.54) |
| Age <50 | 0.68 | 1.11 (0.67–1.84) |
| ER− | 0.36 | 1.45 (0.65–2.23) |
| Triple-negative | 0.23 | 1.65 (0.73–3.73) |
1
The reference race is white.
2
The reference race is non-black.
DRFS = distant recurrence-free survival; ER = estrogen receptor